ATP5F1A and neurodegenerative disease: Results indicated that OMR crossed the BBB more effectively in the multiple dose study than the single dose study suggesting its possible repositioning as antiparkinsonian agent that will be of great impact for researchers concerned with neurodegenerative diseases.